Vancouver, Canada's Zymeworks has its eyes on a big 2014, signing up with Eli Lilly to lend out its cancer-targeting platform and raising $15 million to advance oncology candidates of its own.
Ironwood Pharmaceuticals--which won approval for its irritable bowel syndrome drug Linzess two years ago--is cutting 10% of its workforce in a shakeup. That amounts to about 50 jobs.
Amid AstraZeneca's deal frenzy to rebuild its weak pipeline, the U.K.-based company has forged another research and licensing deal with Horizon Discovery to find new cancer drug targets.
In biomedical research, imitation is now the sincerest form of competition. And the trend is starting to alarm some analysts who see too many biopharma companies trying to compete for a piece of the same small therapeutic franchises.
Back in September, shares of Neurocrine Biosciences were subjected to a beating with the news that the 50-mg dose of its experimental therapy for a rare movement disorder failed the primary endpoint in a Phase IIb study--even though the 100-mg dose performed as hoped.
After several years of setbacks highlighted by one of the worst records for new drug approvals in Big Pharma, Eli Lilly insists that it's prepared to deliver on its long-standing promise to launch "multiple products each year for the next few years" even as it preps big cuts to its R&D budget.
The wave of new drug approvals that had been building at the FDA has broken. According to the official tally of new drug and biologics approvals at the agency, the biopharma industry registered only 27 OKs for new entities in 2013--a sharp plunge from 2012's high of 39 that once again raises big questions about the productivity and sustainability of the world's multibillion-dollar R&D business.
Google Ventures has joined a group of investors seeding DNAnexus' cloud-computing services for biomedical researchers with a $15 million C round.
Big Pharma's decision to shift more of its R&D resources to Asia over the past few years has helped spur a subtle but significant erosion of the U.S.'s traditional dominance in the field.
Can a crop science team of ag-bio investigators provide some real insights that could help advance new drugs for humans and animals? Bayer believes so, and one of its top researchers says you can expect to see the first tangible fruits of its hybrid R&D effort in the next few years.